Genentech to Acquire CDK Inhibitors to treat breast cancer

Regor Pharmaceuticals (USA), a branch of Regor Therapeutics Group, a biotech company in the clinical testing phase, has agreed to a deal where Genentech, part of the Roche Group, will buy a set of advanced CDK inhibitors from Regor to treat breast cancer.

In accordance with the agreement, Regor will be given an initial cash payment of $850 million and may also receive further cash payments depending on specific progress milestones in development, regulation, and sales. Genentech will handle global clinical development, manufacturing, and commercialization duties. Regor will keep overseeing the two phase 1 trials until they finish, and will also progress its separate assets in oncology, metabolic diseases, and auto-immunity.

"Genentech is well-positioned to bring these novel therapeutics to their full potential to benefit patients with breast cancer around the world," said Xiayang Qiu, Ph.D., founder and CEO of Regor. "We are proud of the strong data we have generated to date. We look forward to bringing more innovative therapies to patients around the world."

The planned deal is anticipated to be finalized in the fourth quarter of 2024. The completion of the suggested transaction depends on meeting standard closing requirements. BofA Securities, Inc. is the only financial advisor representing Regor in this deal, while Cohen, Tauber Spievack & Wagner PC and DLA Piper are providing legal counsel.

Regor Pharmaceuticals (USA) is a member of Regor Therapeutics Group, a biotechnology company in the clinical stage creating unique and clinically distinct drugs for untreated health issues in oncology, metabolism, and auto-immune diseases.